Global Viral and Non-Viral Vector Production Market 2023 to 2027: Growing Importance of Cell and Gene Therapy Products Fuels Industry

DUBLIN, July 3, 2023 /PRNewswire/ — The report “Viral & Non-Viral Vector Manufacturing Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027” has been added to ResearchAndMarkets.com offer.

The global Viral and Non-Viral Vector Manufacturing Market is anticipated to observe impressive growth during the forecast period, 2023-2027.

The major factors include the growing prevalence of life-threatening diseases, the growing importance of cell and gene therapy products, and the extensive development of technology, which are driving the growth of the market. Vectors are gene delivery tools, carrying genetic material into the nucleic cell.

They are of two types, viral and non-viral vectors. Viral vectors are delivery vehicles commonly used in FDA-approved gene therapies, while non-virals are still being studied for their safety and efficacy.

The other factors supporting the growth of the market are extensive research and development, increasing number of patients, increasing number of clinical trials, various investments from private and public sector, growing prevalence of cell and gene treatments based on carriers, the growing number of collaborations between companies and the high demand for personalized medicines.

Increased prevalence of fatal diseases

The growing presence of genetic diseases, cancers and infectious diseases, such as diabetes, Down syndrome, influenza, liver cancer, Alzheimer’s disease, cardiovascular diseases and others, around the world are reinforcing the growth of market. According to the WHO, cardiovascular disease (CVD) is the leading cause of death worldwide, taking an estimated 17.9 million lives each year.

According to the WHO, cancer is a leading cause of death, reporting nearly 10 million deaths, or nearly one in six deaths in 2020. Due to the growing number of patients affected by these deadly diseases, the demand for carriers for the treatment is on the rise. For example, in 2019, the FDA approved MVA (Modified Vaccinia virus Ankara), under the trade name Jynneos, to prevent both smallpox and monkeypox.

Growing importance of cell and gene therapy products

Gene therapy is a method of treating or preventing disease with the help of genetic material. Advanced cell and gene therapies, using vectors, have had a major impact on the field of biomedicine. After much research, it has been found that vectors are not only used to prevent or treat specific diseases, but with the genetic information they have, they can directly target the cause of the disease and can alter the way a cell works.

The story continues

The increasing prevalence of vector-based cell and gene treatments is also a contributing factor to the growth of the market. Therefore, numerous innovator companies are actively involved in the development and production of viral and non-viral vectors for cell and gene therapies. For example, in 2022, the USFDA approved the second CAR-T therapy called CARVYKTIT, developed by Johnson and Johnson, which is used to treat relapsed or refractory multiple myeloma.

Companies mentioned

• Catalent, Inc.

• FUJIFILM Holding Corporation

• Danher Corporation

• Genscript Biotech Corporation

• Lonza Group AG

• Merck KGaA Inc.

• Oxford Biomedical plc

• Sartorio AG

• Takara Bio Inc.

• Thermo Fisher Scientific Inc

Market segmentation

by carrier type:

for indication:

• Cancer

• Genetic disease

• Infectious disease

• Cardiovascular disease

• Others

by application:

• Gene therapy

• Vaccinology

• Cell therapy

• Others

by Region:

• North America

• United States

• Canada

• Mexico

• Asia-Pacific

• China

• India

• Japan

• Australia

• South Korea

• Europe & CSI

• Germany

• France

• United Kingdom

• Spain

• Italy

• South America

• Brazil

• Argentina

• Colombia

• Middle East & Africa

• South Africa

• Saudi Arabia

• United Arab Emirates

For more information about this report, please visit https://www.researchandmarkets.com/r/2w5tns

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source of international market research reports and market data. We bring you the latest data on international and regional markets, key industries, top companies, new products and the latest trends.

Media contact:

Research and Markets
Laura WoodChief director
press@researchandmarkets.com

For EST office hours call +1-917-300-0470
For US/CAN Toll Free Call +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

View original content: https://www.prnewswire.com/news-releases/global-viral–non-viral-vector-manufacturing-market-2023-to-2027-growing-prominence-of-gene-and- cell -therapeutic-products-feed-the-sector-301869016.html

SOURCE Research and markets